• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

过去二十年意大利肝细胞癌的变化情况。

The changing scenario of hepatocellular carcinoma over the last two decades in Italy.

机构信息

Dipartimento di Medicina Clinica, Unità di Semeiotica Medica, Alma Mater Studiorum-Università di Bologna, Italy.

出版信息

J Hepatol. 2012 Feb;56(2):397-405. doi: 10.1016/j.jhep.2011.05.026. Epub 2011 Jul 12.

DOI:10.1016/j.jhep.2011.05.026
PMID:21756850
Abstract

BACKGROUND & AIMS: This study investigates whether the aetiologic changes in liver disease and the improved management of hepatocellular carcinoma (HCC) have modified the clinical scenario of this tumour over the last 20 years in Italy.

METHODS

Retrospective study based on the analysis of the ITA.LI.CA (Italian Liver Cancer) database including 3027 HCC patients managed in 11 centres. Patients were divided into 3 groups according to the period of HCC diagnosis: 1987-1996 (year of the "Milano criteria" publication), 1997-2001 (year of release of the EASL guidelines for HCC), and 2002-2008.

RESULTS

The significant changes were: (1) progressive patient ageing; (2) increasing prevalence of HCV infection until 2001, with a subsequent decrease, when the alcoholic aetiology increased; (3) liver function improvement, until 2001; (4) increasing "incidental" at the expense of "symptomatic" diagnoses, until 2001; (5) unchanged prevalence of tumours diagnosed during surveillance (around 50%), with an increasing use of the 6-month schedule; (6) favourable HCC "stage migration", until 2001; (7) increasing use of percutaneous ablation; (8) improving survival, until 2001.

CONCLUSIONS

Over the last 20 years, several aetiologic and clinical features regarding HCC have changed. The survival improvement observed until 2001 was due to an increasing number of tumours diagnosed in early stages and in a background of compensated cirrhosis, and a growing and better use of locoregional treatments. However, the prevalence of early cancers and survival did not increase further in the last years, a result inciting national policies aimed at implementing surveillance programmes for at risk patients.

摘要

背景与目的

本研究旨在探讨过去 20 年来,意大利肝病病因学的变化以及肝细胞癌(HCC)管理水平的提高是否改变了该肿瘤的临床状况。

方法

本研究基于对包括 11 个中心的 3027 例 HCC 患者进行分析的 ITA.LI.CA(意大利肝癌)数据库进行回顾性研究。根据 HCC 诊断的时间,患者分为三组:1987-1996 年(“米兰标准”发表的年份)、1997-2001 年(EASL 肝癌指南发布的年份)和 2002-2008 年。

结果

主要变化如下:(1)患者年龄逐渐增大;(2)HCV 感染的流行率不断增加,直至 2001 年,之后由于酒精性病因的增加而有所下降;(3)肝功能不断改善,直至 2001 年;(4)“偶然”诊断的比例不断增加,而“症状性”诊断的比例不断减少,直至 2001 年;(5)处于监测中的肿瘤的流行率(约 50%)保持不变,但使用 6 个月方案的比例增加;(6)HCC“分期转移”有利,直至 2001 年;(7)经皮消融术的应用增加;(8)生存率提高,直至 2001 年。

结论

过去 20 年来,HCC 的病因和临床特征发生了一些变化。2001 年之前生存率的提高归因于越来越多的早期肿瘤和代偿性肝硬化背景下的诊断,以及局部区域治疗的应用不断增加和效果不断改善。然而,近年来早期癌症的流行率和生存率并未进一步提高,这促使国家制定政策,旨在为高危患者实施监测计划。

相似文献

1
The changing scenario of hepatocellular carcinoma over the last two decades in Italy.过去二十年意大利肝细胞癌的变化情况。
J Hepatol. 2012 Feb;56(2):397-405. doi: 10.1016/j.jhep.2011.05.026. Epub 2011 Jul 12.
2
Rise and fall of HCV-related hepatocellular carcinoma in Italy: a long-term survey from the ITA.LI.CA centres.意大利丙型肝炎相关肝细胞癌的兴衰:来自 ITA.LI.CA 中心的长期调查。
Liver Int. 2013 Oct;33(9):1420-7. doi: 10.1111/liv.12208. Epub 2013 Jun 12.
3
Is female sex a significant favorable prognostic factor in hepatocellular carcinoma?女性性别是否是肝癌的一个显著有利预后因素?
Eur J Gastroenterol Hepatol. 2009 Oct;21(10):1212-8. doi: 10.1097/MEG.0b013e32831a86f8.
4
Impact of evidence-based medicine on the treatment of patients with unresectable hepatocellular carcinoma.循证医学对不可切除肝细胞癌患者治疗的影响。
Aliment Pharmacol Ther. 2010 Feb 15;31(4):493-501. doi: 10.1111/j.1365-2036.2009.04198.x. Epub 2009 Nov 14.
5
Outcomes after curative treatment for cryptogenic cirrhosis-associated hepatocellular carcinoma satisfying the Milan criteria.满足米兰标准的隐源性肝硬化相关肝细胞癌的治愈性治疗后结局。
J Gastroenterol Hepatol. 2011 Sep;26(9):1417-24. doi: 10.1111/j.1440-1746.2011.06775.x.
6
Factors that affect risk for hepatocellular carcinoma and effects of surveillance.影响肝细胞癌风险的因素和监测的效果。
Clin Gastroenterol Hepatol. 2011 Jul;9(7):617-23.e1. doi: 10.1016/j.cgh.2011.03.027. Epub 2011 Apr 1.
7
The evolutionary scenario of hepatocellular carcinoma in Italy: an update.意大利肝细胞癌的进化情况:更新。
Liver Int. 2017 Feb;37(2):259-270. doi: 10.1111/liv.13204. Epub 2016 Aug 17.
8
Treatments for hepatocellular carcinoma in elderly patients are as effective as in younger patients: a 20-year multicentre experience.老年肝细胞癌患者的治疗与年轻患者同样有效:20 年多中心经验。
Gut. 2010 Mar;59(3):387-96. doi: 10.1136/gut.2009.194217.
9
Changes in the characteristics and survival rate of hepatocellular carcinoma from 1976 to 2000: analysis of 1365 patients in a single institution in Japan.1976年至2000年肝细胞癌的特征及生存率变化:对日本一家机构1365例患者的分析
Cancer. 2004 Jun 1;100(11):2415-21. doi: 10.1002/cncr.20289.
10
Surveillance program for early detection of hepatocellular carcinoma in Japan: results of specialized department of liver disease.日本肝细胞癌早期检测监测项目:肝病专科结果
J Clin Gastroenterol. 2006 Nov-Dec;40(10):942-8. doi: 10.1097/01.mcg.0000225675.14594.d6.

引用本文的文献

1
Hepatocellular Carcinoma After HCV Eradication with Direct-Acting Antivirals: A Reappraisal Based on New Parameters to Assess the Persistence of Risk.直接作用抗病毒药物根除丙型肝炎病毒后发生的肝细胞癌:基于评估风险持续性新参数的重新评估
Cancers (Basel). 2025 Mar 18;17(6):1018. doi: 10.3390/cancers17061018.
2
Epidemiology, therapy and outcome of hepatocellular carcinoma between 2010 and 2019 in Piedmont, Italy.2010年至2019年意大利皮埃蒙特地区肝细胞癌的流行病学、治疗及预后情况
World J Gastrointest Oncol. 2024 Mar 15;16(3):761-772. doi: 10.4251/wjgo.v16.i3.761.
3
The First 30 Years of the Universal Hepatitis-B Vaccination-Program in Italy: A Health Strategy with a Relevant and Favorable Economic-Profile.
意大利乙肝疫苗全民接种计划的前 30 年:具有显著和有利经济效益的卫生策略。
Int J Environ Res Public Health. 2022 Dec 6;19(23):16365. doi: 10.3390/ijerph192316365.
4
Hepatocellular carcinoma in viral and autoimmune liver diseases: Role of CD4+ CD25+ Foxp3+ regulatory T cells in the immune microenvironment.病毒性和自身免疫性肝病中的肝细胞癌:免疫微环境中 CD4+CD25+Foxp3+调节性 T 细胞的作用。
World J Gastroenterol. 2021 Jun 14;27(22):2994-3009. doi: 10.3748/wjg.v27.i22.2994.
5
Regorafenib Combined with Other Systemic Therapies: Exploring Promising Therapeutic Combinations in HCC.瑞戈非尼联合其他全身治疗:探索肝细胞癌中有前景的治疗组合
J Hepatocell Carcinoma. 2021 May 26;8:477-492. doi: 10.2147/JHC.S251729. eCollection 2021.
6
Clinicopathological and prognostic value of preoperative lymphocyte to monocyte ratio for hepatocellular carcinoma following curative resection: A meta-analysis including 4,092 patients.根治性切除术后肝细胞癌患者术前淋巴细胞与单核细胞比值的临床病理及预后价值:一项纳入4092例患者的荟萃分析
Medicine (Baltimore). 2021 Jan 22;100(3):e24153. doi: 10.1097/MD.0000000000024153.
7
Long noncoding RNA LINC00460 conduces to tumor growth and metastasis of hepatocellular carcinoma through miR-342-3p-dependent AGR2 up-regulation.长链非编码 RNA LINC00460 通过 miR-342-3p 依赖的 AGR2 上调促进肝细胞癌的肿瘤生长和转移。
Aging (Albany NY). 2020 Jun 3;12(11):10544-10555. doi: 10.18632/aging.103278.
8
Liver stiffness measured by acoustic radiation force impulse elastography predicted prognoses of hepatocellular carcinoma after radiofrequency ablation.声辐射力脉冲弹性成像技术测量的肝脏硬度可预测肝癌经射频消融治疗后的预后。
Sci Rep. 2020 Feb 6;10(1):2006. doi: 10.1038/s41598-020-58988-3.
9
Clinical outcome indicators in chronic hepatitis B and C: A primer for value-based medicine in hepatology.慢性乙型肝炎和丙型肝炎的临床转归指标:肝病学中基于价值的医学入门。
Liver Int. 2020 Jan;40(1):60-73. doi: 10.1111/liv.14285. Epub 2019 Nov 12.
10
Disease Burden of Hepatocellular Carcinoma: A Global Perspective.肝癌疾病负担:全球视角。
Dig Dis Sci. 2019 Apr;64(4):910-917. doi: 10.1007/s10620-019-05537-2.